Search In this Thesis
   Search In this Thesis  
العنوان
Phase III Randomized Trial Comparing Short-Time Infusion of Oxaliplatin and Capecitabine (XELOX30) with chronomodulated (XELOX30) in Patients with Advanced and/or Metastatic Colorectal Cancer/
المؤلف
Ramadan, Mona Quenawy
هيئة الاعداد
باحث / منى قناوي رمضان
مشرف / سهير حلمى محمود
مشرف / نيفين محمود احمد جادو
مشرف / زينب محمد عبد الحفيظ
مشرف / خالد كمال الدين الغنيمي
الموضوع
Trial Comparing Short-Time Infusion of Oxaliplatin and Capecitabine (XELOX 30) with chronomodulated (XELOX 30- Colorectal Cancer-
تاريخ النشر
2015
عدد الصفحات
174.p;
اللغة
الإنجليزية
الدرجة
الدكتوراه
التخصص
الأشعة والطب النووي والتصوير
تاريخ الإجازة
1/4/2015
مكان الإجازة
جامعة عين شمس - كلية الطب - Clinical Oncology and Nuclear Medicine
الفهرس
Only 14 pages are availabe for public view

from 174

from 174

Abstract

The present study estimated that Xelox chrono may be an active first-line regimen in patients with mCRC. chronomodulated XELOX markedly reduce the overall toxicity, short term oxaliplatin infusion didn’t increase the severity of peripheral neuropathy.
Regarding tolerance, xelox chrono showed better tolerance and fewer complications than standard 5FU-containing regimens. The toxicity most frequently encountered was vomiting (36%).
The efficacy showed an ORR rate of 96% in chrono goup compared to 84% in xelox group and longer overall survival, after minimal follow up period of 6 months.
In conclusion, the present chronomodulated XELOX regimen may reduce overall toxicity and improve efficacy; however, it cannot be excluded that a stricter adherence to the chronomodulated administration schedule could be beneficial. Furthermore, a 30-min infusion of oxaliplatin seems safe and does not increase the severity of peripheral neuropathy.